Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

PAVM

PAVmed Inc

Dec 12 • 04:00PM ET

0.7800

Dollar change -0.0300
Percentage change -3.70	%

Healthcare • Medical Devices • USA • NASD

Peers: AVGR ICAD NUWE MLSS SINT BMTX RVP AXGN BLFS SMLR

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.31	Insider Own	15.97%	Shs Outstand	10.66M	Perf Week	-19.39%
Market Cap	8.64M	Forward P/E	-	EPS next Y	-1.16	Insider Trans	0.00%	Shs Float	9.30M	Perf Month	-30.36%
Income	14.71M	PEG	-	EPS next Q	-0.11	Inst Own	13.58%	Short Float	3.08%	Perf Quarter	-56.18%
Sales	4.03M	P/S	2.14	EPS this Y	127.29%	Inst Trans	1.68%	Short Ratio	4.71	Perf Half Y	-29.73%
Book/sh	-0.76	P/B	-	EPS next Y	-146.40%	ROA	67.04%	Short Interest	0.29M	Perf Year	-76.62%
Cash/sh	0.07	P/C	11.22	EPS next 5Y	-	ROE	-	52W Range	0.60 - 3.83	Perf YTD	-78.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	6.21%	ROI	-	52W High	-79.62%	Beta	0.63
Dividend TTM	-	Quick Ratio	0.05	Sales past 5Y	105.16%	Gross Margin	-104.66%	52W Low	30.02%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	0.06	EPS Y/Y TTM	106.46%	Oper. Margin	-1380.29%	RSI (14)	34.52	Volatility	12.74% 11.64%
Employees	107	Debt/Eq	-	Sales Y/Y TTM	166.27%	Profit Margin	364.77%	Recom	1.67	Target Price	9.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	160.58%	Payout	-	Rel Volume	1.40	Prev Close	0.81
Sales Surprise	-8.90%	EPS Surprise	225.91%	Sales Q/Q	25.92%	Earnings	Nov 14 BMO	Avg Volume	60.79K	Price	0.78
SMA20	-20.53%	SMA50	-25.82%	SMA200	-43.40%	Trades		Volume	85,392	Change	-3.70%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-30-21	Initiated	Cantor Fitzgerald	Overweight	$8
Nov-05-20	Initiated	Ascendiant Capital Markets	Buy	$5
Jun-28-18	Initiated	Maxim Group	Buy	$5

Dec-11-24 08:01AM	Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard Esophageal DNA Test Accepted for Peer-Reviewed Publication (PR Newswire)
Dec-03-24 08:01AM	Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones (PR Newswire) +6.31%
Nov-20-24 07:56AM	Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard Esophageal DNA Test (PR Newswire)
Nov-18-24 08:15AM	Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (PR Newswire) -10.53%
Nov-14-24 08:01AM	PAVmed Provides Business Update and Third Quarter 2024 Financial Results (PR Newswire) +6.86%
08:01AM	Loading…
Nov-13-24 08:01AM	Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results (PR Newswire) -8.93%
Nov-07-24 08:01AM	Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing Accepted for Peer-Reviewed Publication (PR Newswire)
Nov-05-24 08:01AM	Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers (PR Newswire)
Oct-31-24 08:31AM	PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 (PR Newswire)
Oct-30-24 08:31AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024 (PR Newswire)
Oct-15-24 07:51AM	Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test (PR Newswire) -8.18%
Oct-10-24 07:51AM	PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care (PR Newswire) -6.40%
Oct-09-24 08:01AM	Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit (PR Newswire)
Oct-08-24 07:49AM	Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024 (PR Newswire)
Oct-01-24 08:01AM	Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players (PR Newswire) +8.13%
08:01AM	Loading…
Sep-24-24 08:01AM	American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test (PR Newswire)
Sep-16-24 04:30PM	PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements (PR Newswire)
Sep-10-24 07:56AM	Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress (PR Newswire) +43.70%
Sep-03-24 07:51AM	Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health (PR Newswire) +30.42%
Aug-20-24 08:16AM	Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard for Early Detection of Esophageal Precancer and Cancer (PR Newswire)
Aug-13-24 08:16AM	The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard to Enhance Early Detection of Esophageal Cancer (PR Newswire) -7.50%
08:01AM	PAVmed Provides Business Update and Second Quarter 2024 Financial Results (PR Newswire)
Aug-12-24 08:07AM	Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results (PR Newswire)
Aug-08-24 08:31AM	Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard #CheckYourFoodTube Precancer Testing Event (PR Newswire)
Aug-06-24 08:15AM	Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard Esophageal Precancer Testing (PR Newswire)
Aug-05-24 08:15AM	Lucid Diagnostics to Participate in Upcoming Investor Conferences (PR Newswire)
Jul-30-24 08:15AM	PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024 (PR Newswire) -15.84%
Jul-29-24 08:15AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024 (PR Newswire)
Jul-23-24 08:01AM	Lucid Diagnostics Announces Record Quarterly EsoGuard Test Volume (PR Newswire)
Jul-11-24 08:31AM	Lucid Diagnostics Launches New Corporate Website (PR Newswire)
07:55AM	Loading…
Jul-02-24 07:55AM	Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing in a Screening Population (PR Newswire) -7.07%
Jun-13-24 07:58AM	PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (PR Newswire) +5.71%
Jun-12-24 08:05AM	4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard Esophageal Precancer Testing (PR Newswire) -9.48%
May-14-24 08:21AM	Lucid Diagnostics Inc. (NASDAQ:LUCD) Q1 2024 Earnings Call Transcript (Insider Monkey) +15.62%
07:53AM	PAVM Stock Earnings: PAVmed Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-13-24 08:43PM	PAVmed Provides Business Update and First Quarter 2024 Financial Results (PR Newswire) -9.43%
08:00AM	Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results (PR Newswire)
May-09-24 07:49AM	Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall (PR Newswire)
May-07-24 07:39AM	Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors (PR Newswire)
May-03-24 08:35AM	PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024 (PR Newswire) -7.59%
May-02-24 08:35AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024 (PR Newswire)
07:49AM	Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing (PR Newswire)
Apr-30-24 07:35AM	PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (PR Newswire) +16.96%
Apr-29-24 08:47AM	Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month (PR Newswire)
Apr-10-24 06:15PM	Why PAVmed Inc. (PAVM) Dipped More Than Broader Market Today (Zacks)
Apr-08-24 08:30AM	Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-28-24 09:47AM	PAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript (Insider Monkey) -21.61%
Mar-27-24 12:35PM	Lucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2023 Earnings Call Transcript (Insider Monkey) +32.52%
05:52AM	PAVM Stock Earnings: PAVmed Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
Mar-26-24 07:32PM	PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results (PR Newswire) -6.79%
Mar-25-24 05:30PM	Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Mar-21-24 09:30AM	Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard Esophageal Precancer Testing in a Screening Population (PR Newswire)
08:30AM	PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX (PR Newswire)
Mar-20-24 08:30AM	Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference (PR Newswire) +7.80%
Mar-13-24 08:30AM	PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024 (PR Newswire) -13.60%
Mar-12-24 08:30AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024 (PR Newswire) +10.13%
Feb-16-24 05:00PM	Lucid Diagnostics Provides Update Regarding World Trade Center Health Program (PR Newswire) +12.82% -11.82%
Feb-15-24 07:45AM	Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck Esophageal Cell Collection Device during Congressional Testimony (PR Newswire)
Feb-08-24 07:45AM	Lucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors (PR Newswire)
Dec-12-23 08:30AM	Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies (PR Newswire) +24.84%
Dec-11-23 09:00AM	PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders (PR Newswire)
Dec-05-23 08:55AM	Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential (InvestorPlace) -19.35%
Dec-04-23 04:20PM	PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split (PR Newswire)
Dec-01-23 10:00AM	Top Penny Stocks for Q4 2023 (Investopedia)
Nov-20-23 12:44PM	PAVmed Inc. (NASDAQ:PAVM) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-16-23 09:07AM	Lucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2023 Earnings Call Transcript (Insider Monkey)
09:00AM	Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts (PR Newswire)
Nov-14-23 05:43PM	PAVmed Provides Business Update and Third Quarter Financial Results (PR Newswire)
Nov-13-23 05:40PM	Lucid Diagnostics Provides Business Update and Third Quarter Financial Results (PR Newswire)
Nov-09-23 09:00AM	Lucid Diagnostics Launches Next-Generation EsoGuard Esophageal DNA Test and Announces Upcoming Investor Day (PR Newswire)
Nov-02-23 09:18AM	Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum (PR Newswire) -5.16%
Nov-01-23 09:10AM	PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2023 (PR Newswire)
Oct-31-23 09:00AM	Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard Esophageal Precancer Detection (PR Newswire)
08:55AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2023 (PR Newswire)
Sep-21-23 08:30AM	PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference (PR Newswire)
Sep-07-23 09:20AM	Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer Detection (PR Newswire) +17.26%
Sep-06-23 09:00AM	Lucid Diagnostics Releases Positive Data Demonstrating Clinical Utility of EsoGuard® Esophageal Precancer Detection in Fire Fighters (PR Newswire) +5.07%
Aug-30-23 09:55AM	Here's Why PAVmed Inc. (PAVM) Is a Great 'Buy the Bottom' Stock Now (Zacks) +35.23%
Aug-24-23 09:00AM	Lucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard® Esophageal Precancer Testing as an Employee Benefit (PR Newswire)
Aug-22-23 05:30PM	PAVmed Inc. (PAVM) Upgraded to Buy: Here's Why (Zacks) +8.40%
Aug-17-23 03:39AM	Q2 2023 PAVmed Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-15-23 08:17PM	PAVmed Provides Business Update and Second Quarter Financial Results (PR Newswire) -6.29% -17.31%
Aug-14-23 06:48PM	Lucid Diagnostics Provides Business Update and Second Quarter Financial Results (PR Newswire) +5.71%
Jul-31-23 06:19PM	PAVmed to Hold a Business Update Conference Call and Webcast on August 16, 2023 (PR Newswire)
06:00PM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 15, 2023 (PR Newswire)
Jul-26-23 08:30AM	Lucid Diagnostics to Present at the Canaccord Genuity 43rd Annual Growth Conference (PR Newswire)
Jul-19-23 09:04AM	PAVmed and Lucid Chairman and Chief Executive Officer, Dr. Lishan Aklog, Testifies at U.S. House of Representatives Energy and Commerce Committee, Hearing on Life-Saving Innovations and Medicare Coverage (PR Newswire)
Jun-28-23 04:05PM	PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire) +13.89%
Jun-14-23 04:05PM	PAVmed to Participate in Healthcare Virtual Conference Presented by Maxim Group LLC (PR Newswire) -6.67% +6.26%
Jun-05-23 07:00AM	Lucid Diagnostics Launches First EsoGuard® Mobile Test Unit (PR Newswire)
Jun-02-23 07:00AM	PAVmed Digital Health Subsidiary, Veris Health, Joins Cancer Moonshot's CancerX Partnership as Founding Member (PR Newswire)
May-24-23 08:00AM	3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024 (InvestorPlace) -7.54%
May-18-23 12:03PM	PAVmed Inc. (NASDAQ:PAVM) Q1 2023 Earnings Call Transcript (Insider Monkey)
12:12AM	Q1 2023 PAVmed Inc Earnings Call (Thomson Reuters StreetEvents)
May-16-23 05:00PM	PAVmed Provides Business Update and First Quarter Financial Results (PR Newswire) -11.39%
May-15-23 06:21PM	Lucid Diagnostics Provides Business Update and First Quarter Financial Results (PR Newswire)
May-11-23 08:45AM	Lucid Diagnostics and Collaborators Present New EsoGuard® and EsoCheck® Data at Digestive Disease Week® (DDW) 2023 Conference (PR Newswire)
May-05-23 09:00AM	PAVmed to Hold a Business Update Conference Call and Webcast on May 17, 2023 (PR Newswire)
09:00AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 16, 2023 (PR Newswire)
Apr-25-23 08:45AM	PAVmed Digital Health Subsidiary, Veris Health, Appoints Gary Manning as President (PR Newswire)

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. The company's products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. PAVmed was founded on June 26, 2014 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
JAMES L. COX	Director	Dec 12 '24	Proposed Sale	0.78	9,469	7,380	Dec 12 05:19 PM
JAMES L. COX	Director	Dec 09 '24	Proposed Sale	0.86	38,095	32,739	Dec 09 05:21 PM
JAMES L. COX	Director	Dec 06 '24	Proposed Sale	1.00	15,600	15,627	Dec 06 05:58 PM
JAMES L. COX	Director	Dec 05 '24	Proposed Sale	1.01	1,836	1,854	Dec 05 05:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PAVM

PAVmed Inc

Upgrade your FINVIZ experience